echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Boshengji Pharma's CAR-T therapy for neuroblastoma has been granted orphan drug designation by the FDA

    Boshengji Pharma's CAR-T therapy for neuroblastoma has been granted orphan drug designation by the FDA

    • Last Update: 2022-04-25
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Transfer from | Medicine Guanlan

    On March 20, Boshengji Pharmaceutical Technology (Suzhou) Co.


    The advent of CAR-T cell therapy is an important breakthrough in the field of cancer


    Neuroblastoma is one of the most common extracranial solid tumors in children with insidious onset and strong heterogeneity


    In order to solve the above challenges, the R&D team of Boshengji Pharmaceuticals has developed TAA06 injection in a targeted manner


    According to the press release, Boshengji Medicine intends to develop TAA06 injection for the treatment of neuroblastoma


    Note: Content has been deleted

    Original title: Boshengji CAR-T product obtained FDA orphan drug designation, targeting neuroblastoma!

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.